Heron Therapeutics Strengthens Leadership with New Board Appointment
Company Announcements

Heron Therapeutics Strengthens Leadership with New Board Appointment

Heron Therapeutics ( (HRTX) ) has provided an update.

Heron Therapeutics has appointed Michael Kaseta to its Board of Directors, bringing his extensive experience in corporate finance and biopharma commercialization to the company. Kaseta, currently the CFO and COO at Liquida Corporation, has a proven track record in financial leadership roles at various pharmaceutical firms. Heron’s CEO, Craig Collard, expressed confidence in Kaseta’s ability to contribute to the company’s growth, particularly in enhancing its portfolio of products aimed at improving patient care.

Find detailed analytics on HRTX stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyElliott confirms big Honeywell stake, Home Deport reports Q3 beat: Morning Buzz
TheFlyHeron Therapeutics reports Q3 EPS (3c), consensus (3c)
TheFlyHeron Therapeutics narrows 2024 revenue view to $140M-$146M from $138M-$158M
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App